



## **ReNetX Adds Strategic Drug Development Regulatory Expert to Scientific Advisory Board**

New Haven, Conn., Sep. 25, 2020 -- ReNetX Bio, Inc., a biotechnology company advancing first-in-class disease-modifying therapeutics for patients with chronic spinal cord injury, has announced the addition of Dr. Kevin Malobisky to their Scientific Advisory Board. Dr. Malobisky, currently the Chief Regulatory and Strategic Operations Officer at Tavanta Therapeutics, brings over 30 years of executive leadership and global drug development experience to the advisory role.

At Achillion Pharmaceuticals, where he was Senior Vice President of Global Regulatory Affairs, Quality, and Compliance, Dr. Malobisky obtained FDA Breakthrough Therapy Designation for an innovative small molecule to treat the rare orphan disease paroxysmal nocturnal hemoglobinuria and helped lead the company to a \$930 million acquisition by Alexion Pharmaceuticals last year. At Karyopharm Therapeutics, where Dr. Malobisky was the Senior Vice President of Global Regulatory Affairs, Quality, and Pharmacovigilance, he led the company's first successful New Drug Application submission under FDA Fast Track Designation for a first-in-class small molecule to treat relapsed or refractory multiple myeloma.

"Dr. Malobisky brings extensive experience and success in achieving significant regulatory milestones such as Breakthrough Therapy and Fast Track Designation for novel therapies," said ReNetX CEO Erika R. Smith. "We are thrilled to welcome him to the SAB for clinical development and regulatory strategy as we continue to advance our lead compound in clinical trials."

Dr. Malobisky has particular expertise in helping small companies deliver on big potential and hopes to do the same for ReNetX. "The innovative translational science may have significant promise and potential for addressing the unmet medical need for people with spinal cord injuries," he said. "I look forward to working with the ReNetX team on advancing these programs through the clinic."

The lead compound from ReNetX, AXER-204, uses a novel approach to block the axon growth inhibitory pathway to allow for axon growth and recovery following spinal cord injury. The therapeutic, based on cutting-edge research by Dr. Stephen Strittmatter of Yale University, has far-reaching potential for treating neurological injury and neurodegenerative diseases. The drug is currently in clinical trials for the treatment of chronic spinal cord injury.

**About ReNetX Bio, Inc.:** For more information, please visit [www.renetx.com](http://www.renetx.com)